Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Provides Notice on Convertible Debentures

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today provided notice to holders of certain bonds have the right to convert the debentures.

The firm said that holders of Apogent Technologies' Floating Rate Convertible Senior Debentures due 2033 may convert the debentures because Thermo Fisher's stock has traded above the minimum price specified in the indenture over the applicable measurement period.

Thermo Fisher assumed the debentures as part of its acquisition of Apogent in 2004.

The firm said that the debentures continue to be convertible until Sep. 26, 2009, and may be convertible thereafter, depending on whether or not one of the conversion conditions specified in the indenture is satisfied during future measurement periods. Thermo Fisher said that if it receives conversion requests, it has the right to decide whether to pay bond holders in cash or a combination of cash and shares of its common stock.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.